AARD · Insider Trading
Aardvark Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by AARD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-08 | Zhongwei Zhang | Director | A | +127,061 deriv. | — |
| 2026-09-11 | Nelson Sun | See Remarks | Sell | −76,754 | −$394.96K |
| 2026-08-21 | Jeffrey Chi | Director | A | +44,964 deriv. | — |
| 2026-08-21 | Roy D. Baynes | Director | A | +44,964 deriv. | — |
| 2026-08-21 | Susan E Graf | Director | A | +44,964 deriv. | — |
| 2026-08-21 | Victor Edward Tong Jr | Director | A | +44,964 deriv. | — |
| 2026-02-11 | Tien-Li Lee | Chief Executive Officer | A | −203,851 deriv. | — |
| 2026-02-11 | Manasi Jaiman | Chief Medical Officer | A | −70,549 deriv. | — |
| 2026-02-11 | Nelson Sun | Chief Financial Officer | A | −70,549 deriv. | — |
| 2025-12-12 | Tien-Li Lee | Chief Executive Officer | Buy | +7,000 | +$101.39K |
| 2025-12-12 | Nelson Sun | Chief Financial Officer | Buy | +3,000 | +$43.20K |
| 2025-10-16 | Bryan Jones | Chief Operating Officer | M | +1,250 | +$5.30K |
| 2025-10-16 | Tien-Li Lee | Chief Executive Officer | M | +1,229 | +$5.21K |
| 2025-09-16 | Tien-Li Lee | Chief Executive Officer | Buy | +10,000 | +$96.62K |
| 2025-09-12 | Tien-Li Lee | Chief Executive Officer | Buy | +20,000 | +$160.65K |
| 2025-09-10 | Nelson Sun | Chief Financial Officer | Buy | +6,000 | +$48.44K |
| 2025-08-29 | Tien-Li Lee | Chief Executive Officer | M | +17,209 | +$72.97K |
| 2025-06-13 | Susan E Graf | Director | A | +30,508 deriv. | — |
| 2025-06-13 | Roy D. Baynes | Director | A | +30,508 deriv. | — |
| 2025-06-13 | Victor Edward Tong Jr | Director | A | +61,017 deriv. | — |
| 2025-06-13 | Bryan Jones | Chief Operating Officer | A | +122,033 deriv. | — |
| 2025-06-13 | Nelson Sun | Chief Financial Officer | A | +209,826 deriv. | — |
| 2025-06-13 | Tien-Li Lee | Chief Executive Officer | A | +549,534 deriv. | — |
| 2025-06-13 | Manasi Jaiman | Chief Medical Officer | A | +126,999 deriv. | — |
| 2025-06-13 | Jeffrey Chi | Director | A | +61,017 deriv. | — |
| 2025-02-19 | Bihua Chen | — | MIXED | +1,975,378 | +$6.00M |
| 2025-02-19 | Tien-Li Lee | Chief Executive Officer | MIXED | +57,845 | +$264.67K |
| 2025-02-19 | Nelson Sun | Chief Financial Officer | MIXED | +17,001 | +$160.00K |
| 2025-02-19 | Jeffrey Chi | Director | C | +133,364 | — |
| 2025-02-19 | Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | MIXED | +19,586,495 | +$100.00M |
| 2025-02-19 | Vickers Venture Fund VI Pte Ltd | 10%+ Owner | C | +2,050,902 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Tien-Li Lee | Chief Executive Officer | 3,025,641 | $3.27M |
| Decheng Capital Global Healthcare GP, LLC | 10%+ Owner | 2,333,887 | $2.52M |
| Vickers Venture Fund VI Pte Ltd | 10%+ Owner | 2,050,902 | $2.21M |
| Bihua Chen | — | 800,189 | $864.20K |
| Jeffrey Chi | Director | 133,364 | $144.03K |
| Nelson Sun | See Remarks | 97,475 | $105.27K |
| Bryan Jones | Chief Operating Officer | 1,250 | $1.35K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AARD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.